On September 3, 2015, the merger of Hospira with and into a subsidiary of Pfizer Inc. (“Pfizer”) was completed. As a result of the merger, the Hospira common stock ceased trading on the New York Stock Exchange and former Hospira shareholders became entitled to receive the per share merger consideration (“merger consideration”) of $90.00, in cash (without interest and less any applicable withholding and transfer taxes) for each share of Hospira common stock they owned as of September 3, 2015, unless they have properly exercised and perfected and not withdrawn their demand for appraisal rights under Delaware law with respect to such shares. For example, if you own 100 shares of Hospira common stock, you will receive $9,000 in cash, less any applicable withholding taxes, in exchange for your shares of Hospira common stock. All shares converted into the right to receive the merger consideration will automatically be canceled at the effective time of the merger.
For Hospira registered shareholders, Pfizer has appointed Computershare Trust Company, N.A. (“Computershare”) as paying agent for payment of the merger consideration. Information concerning the exchange of Hospira shares for the per share merger consideration has been mailed to Hospira registered shareholders, outlining the steps to be taken to obtain the merger consideration. Registered shareholders do not need to take any action regarding their shares until contacted by the paying agent. For additional information, please contact Computershare at 1-800-546-5141 (within the U.S., its territories and Canada) or +1-781-575-2765 (outside the U.S., its territories and Canada).
If you own your shares through a bank, brokerage firm or other nominee (in “street name”), please contact your bank, broker or nominee for further information about receiving the merger consideration.